In plain words

One trial found less weight regain with pasteurized Akkermansia than placebo, and another found a smaller drop that missed statistical significance. A third said an enriched dairy product may help weight management. In a fourth, weight fell in both groups alike, except among people starting with little Akkermansia in the gut.

The short answer

Three of the four randomized trials on this page lean toward lower weight or less regain; the ledger has no doses. A 24-week trial in 90 adults found 1.2 kg regained on pasteurized Akkermansia versus 3.2 kg on placebo (2026). A 3-month trial (2019; no n in the ledger) found a 2.27 kg larger drop that missed significance. An 8-week trial in 66 adults concluded a dairy product may help weight management (2025). A 12-week trial in 58 people with type 2 diabetes found no group difference, except among those starting with little Akkermansia (2025). Certainty is low: each small trial tested a different product, and none was repeated.

Where the evidence sits

Lower weight or less regain

■ Randomized trial, Mount et al., 2026 · 90 people · 24 weeks
■ Randomized trial, Depommier et al., 2019 · ledger has no n · also reported by Dr. Michael Ruscio, 2024
■ Randomized trial, Aalipanah et al., 2025 · 66 people · 8 weeks

No difference between groups

■ Randomized trial, Zhang et al., 2025 · 58 people · 12 weeks · drop in low-baseline subgroup

■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data

Evidence weight5959 / 100?

Who says what

SourceFindingDesignPeopleDose and lengthFunding and independence
Mount et al., 2026Less regain: 1.2 vs 3.2 kgRandomized, placebo-controlled90Not in ledger; 24 weeksNot in ledger
Depommier et al., 20192.27 kg lower, not significantRandomized, placebo-controlledNot in ledgerNot in ledger; 3 monthsNot in ledger
Aalipanah et al., 2025May help weight managementRandomized trial66Not in ledger; 8 weeksNot in ledger
Zhang et al., 2025No group difference; drop if starting levels lowRandomized, placebo-controlled58Not in ledger; 12 weeksNot in ledger
Ruscio, 20245 lbs more lost, "pretty minimal"Practitioner commentary describing a randomized trialNone3 monthsRe-reads a trial, not new data
Roshanravan et al., 2021More trials neededReview authors' conclusionNoneNoneNot in ledger
Mount et al., 2026

Less regain: 1.2 vs 3.2 kg

Design
Randomized, placebo-controlled
People
90
Dose and length
Not in ledger; 24 weeks
Funding
Not in ledger
Depommier et al., 2019

2.27 kg lower, not significant

Design
Randomized, placebo-controlled
People
Not in ledger
Dose and length
Not in ledger; 3 months
Funding
Not in ledger
Aalipanah et al., 2025

May help weight management

Design
Randomized trial
People
66
Dose and length
Not in ledger; 8 weeks
Funding
Not in ledger
Zhang et al., 2025

No group difference; drop if starting levels low

Design
Randomized, placebo-controlled
People
58
Dose and length
Not in ledger; 12 weeks
Funding
Not in ledger
Ruscio, 2024

5 lbs more lost, "pretty minimal"

Design
Practitioner commentary describing a randomized trial
People
None
Dose and length
3 months
Funding
Re-reads a trial, not new data
Roshanravan et al., 2021

More trials needed

Design
Review authors' conclusion
People
None
Dose and length
None
Funding
Not in ledger

Did it help people keep lost weight off?

Mount and colleagues (2026) randomized 90 adults with overweight or obesity who had lost weight on a diet to pasteurized Akkermansia or placebo for a 24-week maintenance period; the ledger has no dose for it.

Here we show that MucT led to lower body weight regain versus placebo at the end of the weight maintenance period (MucT: 1.2 ± 0.7 kg, placebo: 3.2 ± 0.4 kg, P = 0.012).

What did the shorter trials find?

Depommier and colleagues (2019) gave overweight, insulin-resistant adults live or pasteurized Akkermansia for 3 months; the ledger has no n or dose for it.

Pasteurized A.muciniphila supplementation slightly decreased body weight (-2.27±0.92kg, P=0.091) as compared to the Placebo group

Michael Ruscio, DC (2024), describes a small 3-month trial that appears to be this one, reports 5 lbs more lost than on placebo, and calls that pretty minimal.

Aalipanah and colleagues (2025) tested a dairy product enriched with an Akkermansia postbiotic in 66 adults with overweight or obesity for 8 weeks; the ledger has no dose or weight figures for it. They concluded it may have favorable effects on weight management.

Did it matter who took it?

Zhang and colleagues (2025) gave the AKK-WST01 strain or placebo to 58 people with type 2 diabetes and overweight or obesity for 12 weeks; the ledger has no dose for it.

Both groups showed decreases in body weight and glycated hemoglobin (HbA1c), without significant between-group differences.

In people starting with little Akkermansia in the gut, the authors report significant drops in weight and fat mass not seen on placebo. In people starting with a lot, the strain settled poorly and brought no significant clinical improvement.

Why the sources disagree

No two measurements in the ledger contradict each other outright. The trials differ in people (after diet-led weight loss, adults with overweight, type 2 diabetes), in product (a pasteurized strain, a dairy postbiotic, AKK-WST01) and in measure (regain against weight change), over 8 to 24 weeks. The commentary differs in tone: Ruscio (2024) calls the 3-month trial's gap pretty minimal, and Roshanravan and colleagues (2021) wrote that future clinical trials are needed to verify the benefits for obesity.

What would settle it

A placebo-controlled randomized trial of one defined Akkermansia product at a stated daily dose for at least 24 weeks in adults with overweight, with weight change as the pre-registered main outcome, analyzed by starting gut Akkermansia level. A matching result from a second, independent research group would move certainty toward moderate.

How this page was made

The 6 sources are four randomized trials, a 2021 review and a practitioner web page, found through a literature search. Animal studies, and trials that gave other supplements and measured Akkermansia as an outcome, were left out. Every claim was copied word for word into the Longevity Circle ledger and checked against the original text, and the Longevity Circle evidence editor approved each one. Certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.

Changelog: 29 Sep 2026, first version, 6 sources.